BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//Talks.cam//talks.cam.ac.uk//
X-WR-CALNAME:Talks.cam
BEGIN:VEVENT
SUMMARY:HPV vaccines where to next? - Professor Margaret Stanley\, Departm
 ent of Pathology
DTSTART:20140314T130000Z
DTEND:20140314T140000Z
UID:TALK49336@talks.cam.ac.uk
CONTACT:Dr Tennie Videler
DESCRIPTION:Viral infections cause at least 15% of all cancers\; one of th
 e most important oncogenic viruses is the human papillomavirus (HPV) a cau
 sal agent in 5% of cancers in men and women.  The identification of the ma
 jor oncogenic HPV’s HPV 16 and 18 by Harald zur Hausen was recognised in
  2008 by the award to him of the Nobel Prize in Medicine.  The unfolding o
 f the HPV story started in the 1970’s and has resulted in the developmen
 t of prophylactic vaccines using sophisticated recombinant molecular techn
 iques and protein expression to prevent infection by HPV 16 and 18\, the m
 ost prevalent oncogenic HPVs.  These vaccines are licensed world wide and 
 incorporated into national immunisation programmes in both developed and d
 eveloping countries. In view of the overwhelming data on efficacy and the 
 emerging data on the dramatic population effectiveness in vaccinated women
 \, the questions about the current prophylactic vaccines are no longer abo
 ut efficacy but rather about access and affordability.  Two issues\, reduc
 ing the dosage regimen from 3 doses to 2\, or even 1 and gender neutral va
 ccination - extending the benefits of HPV vaccination to boys and men are 
 intensely discussed.  These discussions are complicated by the absence of 
 an immune correlate and the observation that men make poor immune response
 s to HPV.\n.\n
LOCATION:Sackler Lecture Theatre (Level 7)\, Cambridge Institute for Medic
 al Research
END:VEVENT
END:VCALENDAR